Goodwin advised UroMems, an innovative medtech company, in its €14 million fundraising to finance the development of its artificial urinary sphincter. The amount raised includes €2 million from the Worldwide Innovation Challenge within the framework of the French Program of investments for the future led by the General Investment Commission and operated by Bpifrance.
Founded in 2011, UroMems focuses on designing, developing and commercializing active implantable medical devices. The company is based at the heart of the French Alps, in the city of Grenoble, ranked by Forbes in the 5th position of the 15 most innovative cities of the world. The company’s headquarters are located in Minatec, the European innovation campus for micro and nanotechnology.
The Goodwin team advising UroMems was led by partner Christophe Digoy and associate Thomas Dupont-Sentilles.
For more information on the transaction, please view the press release.